15-Year watch begins for experimental transplant therapy

NCT ID NCT05987527

Ongoing Disease control Sponsor: Sangamo Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 11 kidney transplant patients who received an experimental cell therapy called TX200-TR101 in an earlier trial. Researchers will monitor them for up to 15 years to check for long-term side effects and how well their transplanted kidney is doing. The goal is to see if this personalized therapy is safe over time.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TX200-TR101 (a personalized cell therapy using the patient's own modified immune cells)
What this could lead to: If successful, this could show that TX200-TR101 is safe over many years and may help reduce the need for lifelong anti-rejection drugs in kidney transplant patients.
What could go wrong: This is a small, early follow-up study (only 11 people) and does not test whether the therapy works. Long-term risks or side effects may still emerge.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for END-STAGE RENAL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease end stage renal failure transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

END-STAGE RENAL DISEASE KIDNEY TRANSPLANT REJECTION

Contacts and locations

Locations

Erasmus MC, University Medical Center

Rotterdam, Netherlands
Leiden University Medical Centre

Leiden, Netherlands
Oxford University Hospitals NHS Foundation Trust

Oxford, United Kingdom
University Hospitals Leuven

Leuven, Belgium
University Medical Center Groningen

Groningen, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.